Despite an 11% increase in sales (from $1 billion to $1.1 billion a year ago), the company incurred a net loss of $194 million (-56 cents per share). Analysts were projecting a net profit for the company.
STJ received FDA Approval For Epic Stented Tissue Valve, which it plans to roll out in 2008.